Dr. Shah on Updated Results With Trastuzumab Deruxtecan in DESTINY-Gastric01
July 23rd 2020Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.